Patient adherence, injection prevention, increased drug production and self-administration are some of the key drivers behind the estimated 6.4% annual growth of unit dose containers, and it is expected to reach $57.9 billion by the end of 2025, according to new analysis from Freedonia Group.
The blister packaging for solid dose applications will dominate the global market. Parenteral vials and pre-fillable syringes will see the fastest growth. Improving patient compliance through package design is one of the significant trends supporting the unit dose market. This will speed up the use of pads and pads. Clinical drug trials will drive growth prospects for unit-dose packaging systems that promote record keeping and compliance.
The Freedonia Group the analysis predicts that due to the increased need for better infection control systems, the use of adaptable pen cartridges, self-retracting pre-fillable syringes and high barrier parenteral vials would increase in the global medical community. It is a response to the need to improve infection prevention systems.
Bulb growth is driven by competition
Increasing competition between private label and generic is driving drug manufacturers to improve packaging to influence the purchasing decisions of medical providers and consumers.
According to Freedonia analyst Bill Martineau, downward pricing pressures imposed by private and public health insurers are driving competition between individual and general brands. In addition, due to acquisitions and mergers, the number of exclusive drug distributors and manufacturers is slightly decreasing and the number of generic distributors and producers is increasing.
Efforts to improve the convenience and aesthetic properties of pharmaceutical packaging apply overwhelmingly to over-the-counter supplements and medications sold in retail stores. Additionally, enhancements to ethical drug packaging include ease of delivery and infection prevention features.
Vaccines and new therapies require unit dose syringes
According to the study, biosimilar and new treatments for viral diseases, cancer and several other debilitating conditions will drive the demand for parenteral unit dose vials and pre-fillable syringes. Martineau says that all of these medications are almost always packaged in unit dose containers.
Additionally, current improvements in syringe safety and design are responsible for the increase in therapies approved for self-injection. Hence, this is accelerating the demand for parenteral unit dose vials and pre-fillable syringes. According to Martineau, self-injection therapies are mostly packaged in multi-use devices with single-dose cartridges or syringes.
The increased focus on infection prevention in the parenteral drug delivery system in clinics, hospitals, nursing homes, and physicians’ offices is also contributing to the rise of single-dose parenteral vials and syringes. unitary.
In conclusion, the demand for all these unit formats will increase. It will be the answer to the expansion of global preventive medicine that needs a single-dose, injectable vaccine for diseases like shingles, meningitis, influenza and Covid-19. The medical sector is making drastic progress. So, in the next few years, it will elevate things to a whole new level. With advancements in technology and increased consumer demand, things are going to intensify very soon.